Mesenchymal stem cell ‐based treatments for stroke, neural trauma, and heat stroke

ConclusionThis review offers a testable platform for targeting microglial‐mediated cytokines in clinical trials based upon the rational design of MSC therapy in the future. MSCs that are derived from the placenta provide a great choice for stem cell therapy. Although targeting the microglial activation is an important approach to reduce the burden of the injury, it is not the only one. This review focuses on this specific aspect. Ischemic stroke, neural trauma, and heatstroke all cause cerebral ischemia‐related deficits. Exogenous MSC therapy is promising as a means of augmenting brain ischemia‐induced deficits. MSC may improve outcomes of brain ischemia‐induced deficits by reducing overproduction of proinflammatory cytokines or microglial activation.
Source: Brain and Behavior - Category: Neurology Authors: Tags: Review Source Type: research